Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Revenue Exceeds Expectations; Threats Remain Despite New Launches

This article was originally published in Scrip

Executive Summary

Amgen Inc. reported $5.7bn in third quarter revenue, exceeding analyst estimates by $400m and beating the year-ago period by 14%, but the growth was fueled by a combination of higher demand, product price increases and built-up inventories without significant contributions from new medicines.



Related Companies